Observe Medical (OBSRV) Investor presentation summary

Platform and product

• Sippi is an automated, wireless digital urine meter for ICUs and wards; its second generation with wireless connectivity launched in Q4 2019.

• Sippi includes biofilm control; SippLink transfers data wirelessly, SippSense alerts for biofilm, and SippCoat helps mitigate biofilm build-up.

• The system targets manual measurement accuracy, ICU staff workload and infection-control challenges; manual measurement can take up to 300 staff hours per bed annually.

Market opportunity

• Estimated current potential includes ~0.5M Sippi base units and 30M+ disposable units annually, across ~400,000 ICU beds and 24M annual ICU admissions.

• Post-COVID assumptions indicate +20–30% market growth and potential for +100% global market value growth.

• The Nordics and Europe were identified as the priority, with estimated Sippi market value growth of up to 3x post-COVID, driven by capacity needs and staff constraints.

Commercial execution

• Customer prospects were delayed during acute COVID-19, but prospects showed commitment to Sippi use and implementation; efforts focused on regaining customer access.

• Advisory Board input supported the system’s relevance for reducing nurse workload and contamination risk, and for intermediary care wards and online urine monitoring.

• Commercial support included market research, customer contact, life-sciences organizations and clusters to inform the go-to-market strategy.